TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

OPTISON

ALBUMIN HUMAN
Cardiovascular Approved 1997-12-31
3
Indications
--
Phase 3 Trials
28
Years on Market

Details

Status
Prescription
First Approved
1997-12-31
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: ALBUMIN HUMAN

OPTISON Approval History

Loading approval history...

What OPTISON Treats

12 indications

OPTISON is approved for 12 conditions since its original approval in 1997. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hypovolemia
  • Ascites
  • Hypoalbuminemia
  • Burns
  • Acute Nephrosis
  • Acute Respiratory Distress Syndrome
  • Cardiopulmonary Bypass
  • Liver Cirrhosis
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

OPTISON FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

ALBUMINEX 25% is a 25% albumin solution indicated for adults and children : Hypovolemia Ascites Hypoalbuminemia including from burns Acute Nephrosis Acute Respiratory Distress Syndrome (ARDS) Cardiopulmonary Bypass 1.1 Hypovolemia ALBUMINEX 25% is indicated for restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated, and use of a colloid is appropriate e.g. hypovolemia following shock due to trauma or sepsis, in surgical patients and in other similar conditions with volume deficiency when restoration and maintenance of circulating blood volume is r...

OPTISON Patents & Exclusivity

Exclusivity: May 2028

Exclusivity

NPP Until May 2028
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.